BioStem Technologies, Inc. Research and Development Expense
BioStem Technologies, Inc. (BSEM) reported Research and Development Expense of $733.62 thousand for the 3-month period ending 2026-06-30, per its S-1 filed 2026-09-18.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-09-18
- BioStem Technologies, Inc. research and development expense for the quarter ending 2026-06-30 was $733.62K, a 62.52% decline year-over-year.
- BioStem Technologies, Inc. research and development expense for the quarter ending 2025-06-30 was $1.96M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 12 month |
|---|---|---|---|
| 2026-06-30 | $733.62K S-1 · filed 2026-09-18 | $1.87M S-1 · filed 2026-09-18 | |
| 2025-12-31 | $7.09M S-1 · filed 2026-09-18 | ||
| 2025-06-30 | $1.96M S-1 · filed 2026-09-18 | $3.65M S-1 · filed 2026-09-18 | |
| 2024-12-31 | $1.91M S-1 · filed 2026-09-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |